ArticleBMC neurology2026
Association between stress hyperglycemia ratio and early neurological deterioration after acute ischemic stroke: a retrospective cohort study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundStress hyperglycemia ratio (SHR) has emerged as a more accurate indicator of stress-related hyperglycemia than absolute glucose levels. However, its relationship with early neurological deterioration (END) after acute ischemic stroke (AIS) remains unclear.
methodsWe retrospectively analyzed 1,479 AIS patients admitted within 24 h of symptom onset. END was defined as an increase of ≥ 2 points in the NIHSS total or motor score within 72 h. SHR was calculated as the ratio of fasting plasma glucose to estimated average glucose derived from HbA1c and categorized into quartiles. Logistic regression, generalized additive models (GAM), two-piecewise logistic regression, and statistical mediation analyses were performed.
resultsAmong 1,479 patients, 270 (18.3%) developed END. Higher SHR was independently associated with increased END risk (fully adjusted OR = 6.19, 95% CI: 2.68–14.28, P < 0.0001), showing a clear dose-response relationship across quartiles (P for trend = 0.0015). GAM revealed a non-linear relationship, and two-piecewise regression identified a potential inflection point at SHR ≈ 1.06. Subgroup analysis showed a stronger association in non-diabetic patients (interaction P = 0.0033), with no significant interactions for other variables. Sensitivity analysis adjusting for C-reactive protein (CRP) and white blood cell (WBC) count remained robust after adjustment. Mediation analysis indicated that CRP and WBC were statistically associated with the SHR-END relationship, with mediation proportions of 12.89% and 8.03%, respectively.
conclusionsElevated SHR was associated with an increased risk of early neurological deterioration in patients with acute ischemic stroke, following a non-linear pattern without a defined threshold. The association was more pronounced in non-diabetic patients, suggesting heterogeneity across metabolic subgroups. These findings support the potential value of SHR for early risk stratification and warrant further prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.